

Professor Mauro Giacca

Curriculum vitae



PERSONAL INFORMATION

Nationality: Italian

Work address:

King's College London
School of Cardiovascular and Metabolic Medicine & Sciences
The James Black Centre
125 Coldharbour Lane, London SE5 9NU, United Kingdom
Phone +44 207 848 1309 - Email mauro.giacca@kcl.ac.uk

SCOPUS Author ID: 7005255834

ORCID ID: 0000-0003-2927-7225

EDUCATION

- 1989 PhD, University of Genoa, Italy (Virology)
- 1985 Professional License; Board of Medical Doctors and Surgeons, Italy (OMCEOTS2648)
- 1984 MD; Faculty of Medicine, University of Trieste, Italy. Full marks (110/110 *cum laude*)

CAREER AND POSITIONS

- 2025- *Director*, MRC/BHF Centre of Research Excellence in Advanced Cardiac Therapies (REACT)
- 2024- *Co-director*, British Heart Foundation Centre of Research Excellence, King's College London
- 2021- *Head*, School of Cardiovascular and Metabolic Medicine & Sciences, Faculty of Life Sciences & Medicine, King's College London, UK
- 2019- *Professor of Cardiovascular Sciences*, King's College London, London, UK
- 2014-19 *Director-General*, International Centre for Genetic Engineering and Biotechnology (ICGEB). Trieste (Italy), New Delhi (India) and Cape Town (South Africa). ICGEB is an International Organisation for research and training in the United Nations system (www.icgeb.org)
- 2005- *Full Professor of Molecular Biology*, Department of Medical Sciences, University of Trieste, Italy
- 2004-14 *Director*, Italian Component. ICGEB Trieste, Italy
- 2000-04 *Director*, Molecular Biology Laboratory, Scuola Normale Superiore, Pisa, Italy
- 1995-19 *Senior Scientist and Group Leader*, Molecular Medicine Laboratory, ICGEB Trieste, Italy.
- 1988-94 *Staff Scientist*, Molecular Biology Laboratory, ICGEB Trieste, Italy

COMMISSIONS OF TRUST (selected)

- 2025- Member of the BCVS & GPM Genetic and Genomic Therapy Committee of the Council on Basic Cardiovascular Sciences, American Heart Association (AHA)
- 2025- Member of the Cardiovascular and Muscle Disease Committee of the European Society of Gene & Cell Therapy (ESGCT)
- 2024-26 Chair of the Cardiovascular Gene & Cell Therapy Committee of the American Society of Gene and Cell Therapy (ASGCT)
- 2022- Member of the Telethon Italy Scientific Committee
- 2022-24 Member of the Board of the Council on Basic Cardiovascular Science of the European Society of Cardiology (ESC)
- 2022- Member of the European Society of Cardiology (ESC) Congress Programme Committee
- 2021-23 President of the International Society for Heart Research (ISHR), European Section
- 2021-22 Cardiovascular Theme Lead, NIHR Biomedical Research Centre at Guy's and Saint Thomas' NHS Foundation Trust and King's College
- 2020- Member of the Scientific Advisory Board of Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain

- 2020 Requested to give evidence to the House of Lords Science & Technology Select Committee on the science of COVID-19, House of Lords, UK
- 2019- Member of the Scientific Advisory Board, Scuola Normale Superiore, Pisa, Italy
- 2019- Member of the Steering Group of the King's College London BHF Centre of Excellence on Heart Failure
- 2016-18 Member of the Scientific Council of the of the National Research Council (CNR), Italy - Department of Biomedical Sciences - Ministry of Health, Italy
- 2014-20 Elected member of the Nucleus of the Working Group on Myocardial Function of the European Society of Cardiology (ESC)
- 2015-19 Member of the International Governing Board of the International Centre for Biotechnology at the University of Nigeria Nsukka (UNN), a UNESCO Category II Facility at Nsukka, Nigeria
- 2013-19 Member of the Ethics Committee of the Regione Friuli Venezia Giulia, Italy
- 2013- Member of the Advisory Board of the Cardiovasculair Onderzoek Nederland (CVON) ARENA Programme - The Netherlands
- 2012-16 Expert Member in the National Committee for Biotechnology, Biosafety and Life Sciences (CNBBSV), an advisory body to the President of the Council of Ministries of the Republic of Italy
- 2005-10 Member of the International Advisory Board of the National Center for Genetic Engineering and Biotechnology (BIOTEC) in Bangkok, Thailand
- 2001-05 Member of the Executive Committee of NEST (National Enterprise for NanoScience and NanoTechnology) at the Scuola Normale Superiore in Pisa, Italy.

HONOURS AND AWARDS (selected)

- 2025 Elected Foreign Member of the Polish Academy of Arts and Sciences (PAU), Poland
- 2024 Doctoral Degree (*Doctor medicinae honoris causa*, Faculty of Medicine, Goethe University of Frankfurt, Germany
- 2023 Brutsaert Award, Heart Failure Association (HFA) of the European Society of Cardiology (ESC)
- 2021 Elected Fellow of The Academy of Medical Sciences (FMedSci), United Kingdom
- 2021 Elected Fellow of International Society of Heart Research (FISHR)
- 2020 The Janice Pfeffer Distinguished Lecture Award of the International Society for Heart Research (ISHR)
- 2018 Robert Reneman Lecture Prize 2018. CARIM 2018. Maastricht, The Netherlands
- 2015 2nd "Arturo Falaschi Lecture" - Fondazione Adriano Buzzati-Traverso (FAB-T). Pavia, Italy
- 2015 Certificato di Benemerenza - Associazione Culturale "Cinzia Vitale". Trieste. Italy
- 2015 Premio della Fedeltà al lavoro e del Progresso economico 2015. Diploma di Merito - Premio speciale. Camera di Commercio di Trieste, Italy
- 2016 "Premio Cinzia Vitale" 2016 for distinguished professional activities. Associazione Culturale Onlus "Cinzia Vitale". Trieste, Italy
- 2012 Rotary Foundation of Rotary International. Paul Harris Fellow Award
- 2011 San Giusto d'Oro Prize from the City of Trieste, Italy. The most important award given by the Municipality of Trieste, Italy to a citizen with outstanding international recognition
- 2007 Lenghi-Magrassi International prize for outstanding research in virology, Accademia Nazionale dei Lincei, Italy

LEADERSHIP AND MANAGERIAL RESPONSIBILITIES

- 2021- *Head*, School of Cardiovascular and Metabolic Medicine & Sciences, King's College London. Leadership for over 70 academic research group and overall responsibility for over 300 personnel.
- 2014-19 *Director-General of ICGEB*. Top managerial responsibilities over all the activities of the Centre, including those in its seats in New Delhi, India and Cape Town, South Africa, including over 700 research and administrative personnel. He promoted the establishment of a new ICGEB seat in Thaizou, China. He responded to a Board of Government representatives from over 65 Countries.

2004-14 *Director of ICGEB Italian Component*, Trieste, Italy. Responsibility on more than 200 people representing over 25 nationalities in 18 research groups. He reported to a Council of Scientific Advisors, including various Nobel Laureates.

2000-04 *Director*, Molecular Biology Laboratory, Scuola Normale Superiore, Pisa, Italy

EDITORIAL BOARDS

2019- Circulation (Guest Editor)
2017- Cardiovascular Research (Associate Editor)
2013- Molecular Therapy (Editorial Board)
2009-15 Transcription (Editorial Board)
2009-18 Retrovirology (Editorial Board)
2008-20 BMC Infectious Diseases (Editorial Advisor)
2007-10 Journal of Molecular Medicine
2006-13 Genome Letters

REVIEWER ACTIVITY

Reviewer for over 30 peer-reviewed international journals in the fields of gene therapy, stem cell research and cardiovascular diseases. These include Nature, Nature Medicine, Nature Biotechnology, Science, Science Translational Medicine, The Lancet, Cell Host Microbe, PNAS, Molecular Therapy, the EMBO Journal, Circulation Research and others. Member of Site Visit Panels for various research centres and PIs across Europe. Member of the evaluation committees of various granting programs, including calls from the European Commission (Horizon Programmes) and numerous funding agencies in Italy (MIUR, CNR and MS), France (AFM, ANR, AXA, FRM), Spain, Greece, Israel, UK (MRC and AICR), Switzerland and others. International Chair of the LS2 panel for the Swiss SNSF Advanced Grants in 2023. Since 2020, member of the LS4 panel for the ERC Advanced Grant programme.

SCIENTIFIC INTERESTS

His current research interests focus on the development of nucleic acid therapeutics (RNA, AAV vectors) for cardiac repair, regeneration and gene editing. He has pioneered the concept that cardiac regeneration can be achieved through the simulation of endogenous cardiomyocyte proliferation using small non-coding RNAs. For cardioprotection, he has identified novel cytokines that stimulate protective autophagy and can be administered immediately after myocardial infarction. To achieve precise gene editing, he has developed RNA-based treatments that stimulate homology-directed repair in cardiomyocytes. For over 20 years, he has also investigated the biology of HIV-1 and, in particular, the molecular mechanisms that regulate viral latency in experimental systems and in patients. During the COVID-19 lockdown period in spring 2020, he has studied the mechanisms that regulate SARS-CoV-2 infection and has identified drugs that block Spike-induced cell-cell fusion and viral pathogenicity.

PUBLICATIONS

Highly Cited Researcher 2023, 2025 (Clarivate). Top 2% world scientists 2024 (Stanford/Elsevier). Over 470 publications in peer-reviewed international journals (Citations: >29,000; H index (Scopus): 91; H index (Google Scholar): 110) and over 20 reviews or chapters in published books and university text books. The journals in which he has published include Nature, Science, Cell, Nature Med, Science Transl Med, Circulation, Circ Res, J Clin Invest, and others. He is regularly invited to present his research in seminars and meetings internationally.

MENTORSHIP

Over his career, he has directly supervised the activity of more than 100 PhD students and post-docs, paying special attention to mentoring of early career researchers. Several of his former collaborators hold positions of responsibility in various institutions or universities at the international level. He has served as external examiner of students from numerous European Universities, including the University of Oxford (UK), University of Coimbra (Portugal), the University of Basel (Switzerland), the University of Montpellier (France),

the University of Paris VI (France), the University of Uppsala (Sweden), The University of Maastricht (The Netherlands), in addition to numerous Universities in Italy and the United Kingdom.

GRANTS

Since 2000, he was awarded over 50 grants for his research activity. These include three European Research Council (ERC) Advanced Investigator Grants and one Synergy Grant, two British Heart Foundation (BHF) Programme Grant, two Fondation Leducq Transatlantic Network of Excellence grants and a large grant (£50M) for the creation of MRC/BHF Centre of Research Excellence in Advanced Cardiac Therapies (REACT; King's College London, University of Oxford and University of Edinburgh).

The largest grants since 2010 are listed below.

Project Title	Funding Source	Amount	Period	Role
FunSel: Generation of AAV-based, arrayed libraries for in vivo functional selection	European Commission - European Research Council (ERC) – Advanced Investigator Grant	€1,824,000	2010-15	PI (single applicant)
FIERCE - FInd nEw molecularR and CELLular targets against cancer	Ministero dell'Istruzione, Università e Ricerca (MIUR), Italy - FIRB Projects	€740,000 (5,4 million total)	2011-14	Coordinator and PI
Programming the failing heart to a regenerative state	Fondation Leducq, France. Transatlantic Network of Excellence in Cardiovascular Research	€ 600,944 (€ 4,1M total)	10/2014-09/2019	European Coordinator and PI
SINERGIA - lncRNA in cardiac regeneration	Swiss National Science Foundation, Switzerland	€ 635,000 (€2,5M total)	10/2017-09/2021	PI (Coordinator: T. Pedrazzini)
CuRE - Cardiac regeneration from within	European Commission - European Research Council (ERC) – Advanced Investigator Grant	€2,428,492	2019-24	PI (single applicant)
CARDIOREGENIX - Development of Next-Generation Gene Therapies for Cardiovascular Disease	European Commission - Horizon 2020 RIA	€1,013,675	2019-24	PI (Coordinator: M. Chuah)
REANIMA - New generation cardiac therapeutic strategies directed to the activation of endogenous regenerative mechanisms	European Commission - Horizon 2020 Programme 3.1.3 "Treating and managing disease"	€780,000	2020-2024	PI (Coordinator: M. Torres)
Functional selection of novel biotherapeutics for myocardial infarction and heart failure using arrayed AAV libraries coding for the secretome	British Heart Foundation Programme Grant	£1,430,289	2020-2024	PI
Editing the failing heart	Fondation Leducq, France. Transatlantic Network of Excellence in Cardiovascular Research	€645,000 (\$6.5M total)	2021-24	PI (Coordinators: E. McNally, W. Zimmermann)
Biofoundry-in-A-Box: Modular microfactories for powering the global RNA production network	Wellcome Leap Program - RNA Readiness Response (R3)	£330,167 (£15.9M total)	2021-2024	PI (Coordinator: C. Makatsoris)
TiILT - Preclinical development of a 3rd-generation interleukin-2 targeted to inflammatory sites	European Commission - Horizon 2022 - RIA	£320,000	2023-2028	PI (Coordinator: D. Klatzmann)
GEREMY - Gene Therapy for treatment of rare inherited Arrhythmogenic Cardiomyopathy	European Commission - Horizon 2022 - RIA	£625,500	2023-2028	PI (Coordinator: P. Doevendans)

BHF Centre of Research Excellence Award 4. King's College London	British Heart Foundation, UK	£4,000,000.	2024-29	Co-Director (with A. Shah)
HELP-GT - Small RNA adjuvants for efficient gene therapy and gene editing	European Commission - European Research Council (ERC) – Advanced Investigator Grant	€2,500,00	2025-2029	PI (single applicant)
REACT - MRC/BHF Centre of Research Excellence for Advanced Cardiac Therapeutics	Medical Research Council, British Heart Foundation, UK	€26,500,000	2025-2031	Lead,, Director and PI (with University of Oxford and University of Edinburg)
Development of injectable mRNA therapies for cardioprotection Grant RG/F/24/110150	British Heart Foundation Programme Grant	£1,503,420	2025-2030	PI (single applicant)
ADIPOHealth - Deciphering the role of adipose tissue in cardiac health and disease. Grant 101224726	European Commission - European Research Council (ERC) - Synergy Grant	€2.363.898 (€10.2M total)	2026-2031	PI (Coordinator: G. Sabio)

INVITED SEMINARS (selected)

- 2026 “RNA therapies for the heart”. Peking University Health Science Centre. Beijing, China
- 2025 “RNA therapies for the heart”. Center for Engineering in Medicine & Surgery (CEMS) at Massachusetts General Hospital – Harvard Medical School (on line)
- 2024 “RNA therapies for cardiac repair”. Cardiology Grand Rounds. University Hospital Zurich, Switzerland
- 2022 “RNA therapies for cardiac gene editing and regeneration”. European Vascular Biology Organization (EVBO) (on line)
- 2021 “RNAi therapy for cardiac regeneration (with a detour into SARS-CoV-2 Spike biology”. Imperial College, National Heart and Lung Institute. London, UK
- 2019 “Innovative biotherapeutics for cardiac repair and regeneration”. The University of Oxford, The Radcliffe Department of Medicine. Oxford, UK
- 2017 “Genetic Drugs for Cardiac Repair and Regeneration”. Imperial College, National Heart and Lung Institute. London, UK.
- 2017 “Genetic Drugs for Cardiac Repair and Regeneration”. Stanford University School of Medicine, Stanford Cardiovascular Institute. Stanford, CA, USA.
- 2017 “Genetic Drugs for Cardiac Repair and Regeneration”. University of Colorado, Anschutz Medical Campus, Division of Cardiology. Denver, CO, USA.
- 2016 “AAV libraries for cardiac repair and regeneration”. KU Leuven, VIB Vesalius Research Center, Leuven, Belgium.
- 2015 “Nuclear architecture and the determinants for HIV latency”. Institute Pasteur. Paris, France.
- 2014 “New genes for old hearts”. Munich, Germany. Munich Heart Alliance Lecture Series. Institute of Pharmacology and Toxicology, Technische Universitaet Muenchen
- 2014 “Cytokines and microRNAs that improve cardiac function and induce myocardial regeneration”. Heart Institute. Cedars-Sinai Hospital, Los Angeles
- 2013 “Searching for cytokines and microRNAs inducing cardiac protection and myocardial regeneration”. Brigham and Women's Hospital. Center for Regenerative Medicine. Harvard Medical School. Boston, MA, USA
- 2010 “Searching for genes that induce myocardial protection, myocardial repair or neoangiogenesis by in vivo gene transfer using AAV vectors”. Mount Sinai School of Medicine, New York, NY, USA

INVITED TALKS AND KEYNOTE LECTURES AT MEETINGS (recent, selected)

- 2026 The 10th Cardiovascular Bioengineering (CVBE) Symposium 2026. Goettingen, Germany
- 2026 The 20th Qianjiang Cardiovascular Conference - Basic and Translational Science (QICC-BTS). Hangzhou, China

- 2025 American Heart Association (AHA). Scientific Sessions 2025. New Orleans, LA, USA
- 2025 European Society of Cardiology (ESC) Annual Meeting, Madrid, Spain
- 2025 Basic Cardiovascular Science (BCVS) meeting, American Heart Association, Baltimore, MD, USA
- 2025 Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). New Orleans, LA, USA
- 2025 International Society for Heart Research (ISHR) World Meeting, Nara, Japan
- 2024 European Society of Cardiology (ESC) Annual Meeting, London, United Kingdom
- 2024 International Society for Heart Research (ISHR) European Section Annual Meeting, Toulouse, France
- 2023 The 7th Cardiovascular Bioengineering Symposium (CVBE) 2023, Kyoto, Japan
- 2023 The Brutsaert Lecture. Winter Meeting of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC), Les Diablerets, Switzerland
- 2023 Drug Discovery and Therapeutics Meeting. Abu Dhabi, United Arab Emirates. New York University Abu Dhabi
- 2022 Gordon Research Conference "Cardiac Regulatory Mechanisms". New London, NH, USA
- 2021 EMBO Workshop: Cardiomyocyte Biology. Ascona, Switzerland (on line)
- 2021 Annual Meeting of the International Society for Heart Research (ISHR)-European Section (on line)
- 2021 European Society of Cardiology (ESC) Heart Failure 2021 (on line)
- 2021 "Carlo Urbani" Virtual Symposium on Emerging and Reemerging Viral Diseases. Università Vita-Salute San Raffaele and Carlo Urbani Association Taiwan (on line)
- 2021 European Society of Cardiology (ESC) Congress 2021 (on line)
- 2021 Celebrative Symposium for the 50 years of history of the Faculty of Biochemistry, Biophysics and Biotechnology, Krakow University. Krakow, Poland
- 2021 Online Retreat of the International Max Planck Research School for Molecular Organ Biology - Max Planck Institute for Heart and Lung Research (MPI-HLR) (on line)
- 2021 First International Meeting of the Federation of Stem Cell Associations (StemNet). Padova, Italy.
- 2021 9th Cardiac Regeneration and Vascular Biology Conference. San Servolo (Venice, Italy)
- 2021 Winter School "Stem cells and Molecular Medicine". Rome, Italy (on line)
- 2021 Columbia University COVID-19 Virtual Symposium (on line). Columbia University, New York. USA
- 2021 QU Health Cardiovascular Research Symposium (on line). Qatar University, Doha, Qatar
- 2021 Annual meeting of the Cardiac Society of Australia and New Zealand (CSANZ; on line)
- 2019 Toronto 2019 ISSCR International Symposium "From Stem Cell Biology to New Therapies". Toronto, Canada
- 2019 Wihuri Research Institute Symposium "Translational Insights into Organ-Specific Vasculature". Helsinki, Finland
- 2019 World Congress of the International Society for Heart Research (ISHR). Beijing, China.
- 2019 Nuclear and Cytoplasmic Molecular Machines at Work. New York University Abu Dhabi, United Arab Emirates.
- 2018 American Heart Association (AHA). Scientific Sessions 2018. Chicago, IL, USA
- 2017 20th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). Washington, DC, USA
- 2017 Keystone Symposia Conference "RNA-based Approaches in Cardiovascular Disease". Keystone, CO, USA
- 2016 XXII World Congress of the International Society for Heart Research (ISHR). Buenos Aires, Argentina.

PATENTS (since 2010)

- 2025 Lipid nanoparticles and their use to carry RNA into cardiomyocytes (IPTO 102025000016867)
- 2024 Proteins with cardiopreservation activity (USPTO 63/655,568)
- 2024 Lipid nanoparticles for extra-hepatic diseases (UKIPO submitted)
- 2024 Lipid nanoparticles for cardiac protection (UKIPO submitted)
- 2022 Novel miRNA effectors of vascular smooth muscle cell proliferation (WO-2024038284-A1)

- 2020 Composition and methods for enhancing cardiomyocyte transplant engraftment (WO-2023004345-A1)
- 2020 Method for identifying an agent modulating cell fusion or syncytia formation and compositions for treating coronaviruses
- 2020 Emid2 protein as anti-cancer treatment (US-2023241183-A1)
- 2019 Proteins with cardioprotective activity (US-12121594-B2)
- 2017 MicroRNA hsa-miR-665 in cardiac hypertrophy (US-11155818-B2)
- 2015 Micronas for the treatment of heart diseases (EP-3344768-B1)
- 2011 MicroRNAs for cardiac regeneration through induction of cardiac myocyte proliferation (US-11236332-B2)

INTERACTION WITH INDUSTRY

Founder and board member of Heqet Therapeutics, Torino, Italy which develops microRNA-based therapies for cardiac regeneration; founder of Forcefield Therapeutics Inc, London, UK, which develops cardioprotective therapeutics; co-founder of Purespring Therapeutics Inc, London, which specialises in AAV gene therapy of the kidney. These companies are based on technologies he has developed. 2019-23: member of the Scientific Advisory Boards of Trizell Holding SA, Lausanne and DINAQOR AG, Zurich-London, two companies in the field of gene therapy.

PUBLIC ENGAGEMENT

He is active in the dissemination of science for the general public. Since 2011, he holds the weekly column “*Al microscopio*” (*Under the microscope*) in the Italian newspaper “*Il Piccolo*” (one of the oldest in Italy, founded in 1881), in which he presents scientific topics of general interest. He is the creator of “*Science & The City*”, a series of public events in Trieste, Italy in which leading scientists discuss topics of current scientific relevance with the public. Some of his recent work has received broad visibility in both scientific media (covered by editorials in Nature, Nature Biotechnology, the New England Journal of Medicine) and in media for the general public (including the BBC, Guardian and other magazines in Europe).

Since 2013, registered member of the National Board of Journalists of Italy (N. 152255).

PUBLICATIONS (selected from >470 publications) – all with senior authorship

Tomczyk, M., Kraszewska, I., Li, G., Hayes, M.J., Venditti, L., Huntington, J., Wong, C.K., Cadoni, A., Bortolotti, F., Mura, A., Pachauri, M., Sinagra, G., Giacca, M. 2025. *Chordin-Like 1 mRNA Therapy for Acute Myocardial Infarction*. **Circulation** 152, 1586-1589.

Secco, I., Backovic, A., Tomczyk, M., Mura, A., Li, G., Bortolotti, F., Vodret, S., Dal Ferro, M., Chiavacci, E., Zentilin, L., Sinagra, G., Zacchigna, S., Mano, M., Giacca, M. 2025. *Genetic tracing and topography of spontaneous and stimulated cardiac regeneration in mice*. **Nature Cardiovasc Res** 4, 397–411.

Ruozì G, Bortolotti F, Mura A, Tomczyk M, Falcione A, Martinelli V, Vodret S, Braga L, Dal Ferro M, Cannata A, Zentilin L, Sinagra G, Zacchigna S, Giacca M. *Cardioprotective factors against myocardial infarction selected in vivo from an AAV secretome library*. **Science Transl Med.** 2022. 14, eabo0699.

Braga, L., Ali, H., Secco, I., Chiavacci, E., Neves, G., Goldhill, D., Penn, R., Jimenez-Guardeno, J.M., Ortega-Prieto, A.M., Bussani, R., Cannata, A., Rizzari, G., Collesi, C., Schneider, E., Arosio, D., Shah, A.M., Barclay, W.S., Malim, M.H., Burrone, J., Giacca, M. 2021. *Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia*. **Nature** 594, 88-93.

Gabisonia, K., Prosdocimo, G., Aquaro, G.D., Carlucci, L., Zentilin, L., Secco, I., Ali, H., Braga, L., Gorgodze, N., Bernini, F., Burchielli, S., Collesi, C., Zandona, L., Sinagra, G., Piacenti, M., Zacchigna, S., Bussani, R., Recchia, F.A., Giacca, M. 2019. *MicroRNA therapy stimulates uncontrolled cardiac repair after myocardial infarction in pigs*. **Nature** 569, 418-422.

Marini, B., Kertesz-Farkas, A., Ali, H., Lucic, B., Lisek, K., Manganaro, L., Pongor, S., Luzzati, R., Recchia, A., Mavilio, F., Giacca*, M., Lusic*, M. 2015. *Nuclear architecture dictates HIV-1 integration site selection*. **Nature** 521, 227-31; * last co-authorship.

Eulalio, A., Mano, M., Dal Ferro, M., Zentilin, L., Sinagra, G., Zacchigna, S., Giacca, M. 2012. *Functional screening identifies miRNAs inducing cardiac regeneration*. **Nature** 492, 376-81.